Literature DB >> 27301450

Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.

B Mueller1, D J Salchow1, E Waffenschmidt1, A M Joussen1, G Schmalisch2, Ch Czernik2, Ch Bührer2, K U Schunk3, H J Girschick3, S Winterhalter1.   

Abstract

AIMS: To investigate the outcome of intravitreal bevacizumab (IVB) compared with laser photocoagulation in type I retinopathy of prematurity (ROP).
METHODS: Case records of 54 consecutive very low birth weight (VLBW) infants with type I ROP (posterior ROP, n=33; peripheral zone II, n=21) who were treated either with IVB (n=37) or laser photocoagulation (n=17) between 2011 and 2015 were retrospectively evaluated.
RESULTS: Patients with posterior ROP displayed significantly faster regression of active ROP within 12 days (range 9-15 days) if treated with IVB compared with laser photocoagulation, where active ROP regressed within 57 days (range 28-63 days) (p>0.001). No difference was observed in peripheral zone II.Five of seven patients (12%) who developed a recurrence in both eyes after IVB required additional laser photocoagulation within a mean of 12.7 weeks (11.3-15.6 weeks) after the previous treatment. After laser photocoagulation one patient with posterior ROP developed macular dragging and another patient developed a temporary exudative retinal detachment in both eyes. 12 months after treatment the spherical equivalent was not statistically significant different between IVB and laser photocoagulation in posterior ROP patients. However, IVB lead to a significant lower spherical equivalent in infants with posterior ROP (+0.37 dioptres, range -0.5 to +1.88 dioptres) compared with peripheral zone II (+3.0 dioptres range +2.0 to +4.0 dioptres, p<0.001).
CONCLUSIONS: IVB leads to faster regression of active ROP in infants with posterior ROP compared with laser photocoagulation. Spherical equivalent after 12 months was comparable in those treated with IVB and laser photocoagulation, but it was significantly lower in posterior ROP than in peripheral zone II. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Child health (paediatrics); Neovascularisation; Optics and Refraction; Retina

Mesh:

Substances:

Year:  2016        PMID: 27301450     DOI: 10.1136/bjophthalmol-2016-308375

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  25 in total

1.  Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.

Authors:  Tomoya Murakami; Yoshimi Sugiura; Fumiki Okamoto; Yoshifumi Okamoto; Atsuko Kato; Sujin Hoshi; Motomichi Nagafuji; Yayoi Miyazono; Tetsuro Oshika
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-21       Impact factor: 3.117

Review 2.  Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity.

Authors:  Dana Darwish; Ru-Ik Chee; Samir N Patel; Karyn Jonas; Susan Ostmo; J Peter Campbell; Michael F Chiang; R V Paul Chan
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2018-05-29

3.  Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis.

Authors:  Shi-Dan Wang; Guo-Ming Zhang
Journal:  Int J Ophthalmol       Date:  2020-05-18       Impact factor: 1.779

4.  Role of LASERS in stage 4A retinopathy of prematurity (ROP).

Authors:  Shilpi H Narnaware; Prashant K Bawankule
Journal:  Lasers Med Sci       Date:  2020-09-03       Impact factor: 3.161

5.  [Treated cases of retinopathy of prematurity in Germany : 5-year data from the Retina.net ROP registry].

Authors:  J M Walz; S Bemme; S Reichl; S Akman; H Breuß; D Süsskind; B Glitz; V C Müller; L Wagenfeld; A Gabel-Pfisterer; S Aisenbrey; K Engelmann; A Koutsonas; T U Krohne; A Stahl
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

Review 6.  [Review of clinical trials in retinopathy of prematurity : Current state and future perspectives].

Authors:  Andreas Stahl
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

7.  Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study.

Authors:  Yu-Bai Chou; An-Guor Wang; Hsin-Yu Yang; Kuan-Jung Chen; Chang-Sue Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-22       Impact factor: 3.117

8.  A Quantitative Severity Scale for Retinopathy of Prematurity Using Deep Learning to Monitor Disease Regression After Treatment.

Authors:  Kishan Gupta; J Peter Campbell; Stanford Taylor; James M Brown; Susan Ostmo; R V Paul Chan; Jennifer Dy; Deniz Erdogmus; Stratis Ioannidis; Jayashree Kalpathy-Cramer; Sang J Kim; Michael F Chiang
Journal:  JAMA Ophthalmol       Date:  2019-07-03       Impact factor: 7.389

Review 9.  Role of cytokines and treatment algorithms in retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Curr Opin Ophthalmol       Date:  2017-05       Impact factor: 3.761

10.  Retinopathy of Prematurity: Advances in the Screening and Treatment of Retinopathy of Prematurity Using a Single Center Approach.

Authors:  Audina M Berrocal; Kenneth C Fan; Hasenin Al-Khersan; Catherin I Negron; Timothy Murray
Journal:  Am J Ophthalmol       Date:  2021-07-21       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.